The stock's fall snapped a two-day winning streak.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of ...

Learn more about whether Biogen Inc. or Natera, Inc. is a better investment based on AAII's A+ Investor grades, which compare ...

Biogen (NASDAQ:BIIB) shares experienced a change in market expectations as Cantor Fitzgerald revised the company's price target. The new target has been set at $206.00, a decrease from the previous ...

Biogen Inc.于1985年在加利福尼亚州以IDEC制药公司的名义成立，并于1997年重新注册为特拉华州公司。2003年，他们收购了Biogen, Inc.，并将公司名称更改为Biogen Idec Inc.。该公司是一家全球性的生物制药公司，专注于为患有严重神经和神经退行性疾病的患者以及相关的治疗邻接患者发现、开发和提供全球创新疗法。该公司的核心增长领域包括多发性硬化症（MS）和神经免疫学 ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

Equities research analysts at Wedbush dropped their FY2024 EPS estimates for Biogen in a research report issued on Thursday, ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

Sage Therapeutics stock gained after it announced that its board of directors has rejected the unsolicited, non-binding proposal offer from biotech giant Biogen to acquire the remaining shares of ...